Mycenax Biotech Inc. (TPEX: 4726)
Health Care · Biotechnology · TW
NT$24.80
+1.22% today · -35.2% 1Y
Mycenax Biotech Inc. (TPEX: 4726) operates in the Biotechnology industry within the Health Care sector. The company is valued at $161.40M and employs 387 people.
Over the last twelve months the share price has lost 35.2%, trading between 23.80 and 40.00.
Tweenvest scores Mycenax Biotech Inc. across four factors: quality 42/100, value 72/100, growth 50/100. Its strongest factor is value.
4726 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $161.40M
- Revenue (TTM)
- $25.64M
- P/E
- —
- EPS
- -1.84
- Dividend yield
- —
- Beta (5Y)
- 0.45
- 52-week high
- NT$40.00
- 52-week low
- NT$23.80
- Avg volume (3M)
- —
- Shares outstanding
- 207.23M
- Employees
- 387
- Next earnings
- —
About Mycenax Biotech Inc.
Mycenax Biotech Inc. specializes in the research, development, and manufacturing of biopharmaceutical products, leveraging both mammalian and microbial cell culture systems. Its market reach extends across Taiwan, Europe, Asia, and the United States. The company cultivates a diverse portfolio of advanced biological therapeutics and components. This includes monoclonal antibodies, bi-specific antibodies, Fc-fusion proteins, recombinant proteins, peptides, non-toxic protein conjugates, antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), in addition to plasmids and DNA vaccines. Beyond product innovation, Mycenax offers a comprehensive suite of process development solutions. These encompass the establishment of production cell lines, optimization of upstream and downstream processes, industrial scale-up, formulation science, and the creation of analytical methods. The firm also provides in-house analytical testing, Good Manufacturing Practice (GMP)-compliant manufacturing services for drug substances and finished products, and cell banking, all underpinned by its specialized manufacturing technologies. Established in 2001, Mycenax Biotech Inc. is headquartered in Zhubei, Taiwan.
- ISIN
- TW0004726005
- Founded
- 2001
- Listed since
- Jun 20, 2012
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.